166 related articles for article (PubMed ID: 2527532)
1. Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.
Burnier M; Mooser V; Nussberger J; Waeber B; Brunner HR
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):189S-197S. PubMed ID: 2527532
[TBL] [Abstract][Full Text] [Related]
2. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
Gasic S; Heinz G; Kleinbloesem C; Korn A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):225S-234S. PubMed ID: 2548552
[TBL] [Abstract][Full Text] [Related]
3. Haemodynamic and hormonal effects of cilazapril in comparison with propranolol in healthy subjects and in hypertensive patients.
Kleinbloesem CH; Erb K; Essig J; Breithaupt K; Belz GG
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):309S-315S. PubMed ID: 2527544
[TBL] [Abstract][Full Text] [Related]
4. Effects of single doses of the converting enzyme inhibitor cilazapril in normal volunteers.
Fasanella d'Amore T; Bussien JP; Nussberger J; Waeber B; Turini GA; Brunner HR; Kler L; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):26-31. PubMed ID: 2434790
[TBL] [Abstract][Full Text] [Related]
5. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
Waterfall JF
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
[TBL] [Abstract][Full Text] [Related]
6. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex.
Belz GG; Essig J; Kleinbloesem CH; Hoogkamer JF; Wiegand UW; Wellstein A
Br J Clin Pharmacol; 1988 Nov; 26(5):547-56. PubMed ID: 2974715
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous cilazaprilat in normal volunteers.
Whitehead EM; Walters GE; Williams PE; Johnston GD
Br J Clin Pharmacol; 1989 Jun; 27(6):873-5. PubMed ID: 2757899
[TBL] [Abstract][Full Text] [Related]
8. Repeated administration of the converting enzyme inhibitor cilazapril to normal volunteers.
Nussberger J; Fasanella d'Amore T; Porchet M; Waeber B; Brunner DB; Brunner HR; Kler L; Brown AN; Francis RJ
J Cardiovasc Pharmacol; 1987 Jan; 9(1):39-44. PubMed ID: 2434792
[TBL] [Abstract][Full Text] [Related]
9. The effect of acute ACE inhibition on atrial natriuretic peptide.
Doorenbos CJ; van Brummelen P
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):243S-247S. PubMed ID: 2527537
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the pharmacokinetics and pharmacodynamics of cilazapril between Chinese and Caucasian healthy, normotensive volunteers.
Anderson PJ; Critchley JA; Tomlinson B
Eur J Clin Pharmacol; 1996; 50(1-2):57-62. PubMed ID: 8739812
[TBL] [Abstract][Full Text] [Related]
11. A pharmacokinetic study of cilazapril in elderly and young volunteers.
Williams PE; Brown AN; Rajaguru S; Walters GE; McEwen J; Durnin C
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):211S-215S. PubMed ID: 2527535
[TBL] [Abstract][Full Text] [Related]
12. The cardiovascular and endocrine effects of cilazapril, a new angiotensin-converting enzyme inhibitor, in man.
Ajayi AA; Reid JL
Afr J Med Med Sci; 1990 Mar; 19(1):33-8. PubMed ID: 2139303
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers.
Wellstein A; Essig J; Belz GG
Clin Pharmacol Ther; 1987 Jun; 41(6):639-44. PubMed ID: 3034469
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin-converting enzyme (ACE)-inhibition in cirrhosis. Pharmacokinetics and dynamics of the ACE-inhibitor cilazapril (Ro 31-2848).
Gross V; Treher E; Haag K; Neis W; Wiegand U; Schölmerich J
J Hepatol; 1993 Jan; 17(1):40-7. PubMed ID: 8445218
[TBL] [Abstract][Full Text] [Related]
15. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril.
Massarella JW; DeFeo TM; Brown AN; Lin A; Wills RJ
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):205S-209S. PubMed ID: 2527534
[TBL] [Abstract][Full Text] [Related]
16. The pharmacodynamics and dose-response relationships of the angiotensin converting enzyme inhibitor, cilazapril, in essential hypertension.
Ajayi AA; Elliott HL; Reid JL
Br J Clin Pharmacol; 1986 Aug; 22(2):167-75. PubMed ID: 3019375
[TBL] [Abstract][Full Text] [Related]
17. The pharmacokinetics and bioavailability of cilazapril in normal man.
Williams PE; Brown AN; Rajaguru S; Francis RJ; Walters GE; McEwen J; Durnin C
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):181S-188S. PubMed ID: 2527531
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of the new angiotensin-converting-enzyme inhibitor, cilazapril, in anesthetized and conscious dogs.
Holck M; Fischli W; Hefti F; Gerold M
J Cardiovasc Pharmacol; 1986; 8(1):99-108. PubMed ID: 2419701
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetics and dose proportionality of cilazapril.
Massarella J; DeFeo T; Lin A; Limjuco R; Brown A
Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):199S-204S. PubMed ID: 2527533
[TBL] [Abstract][Full Text] [Related]
20. Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties.
Eichler HG; Blöchl-Daum B; Kyrle PA; Gasic S
J Cardiovasc Pharmacol; 1989 Aug; 14(2):248-52. PubMed ID: 2476598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
